264 related articles for article (PubMed ID: 25036475)
1. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
2. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
3. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
Carver KH; Elikan J; Lietzan E
Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
Dranitsaris G; Amir E; Dorward K
Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
[TBL] [Abstract][Full Text] [Related]
5. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: policy, clinical, and regulatory considerations.
Gottlieb S
Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
[TBL] [Abstract][Full Text] [Related]
7. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
Miller KL; Lanthier M
Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
[No Abstract] [Full Text] [Related]
8. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
9. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
10. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilars versus original biologics. Similarities and differences from development to approval].
Windisch J
Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
[TBL] [Abstract][Full Text] [Related]
12. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
13. The US approach to biosimilars: the long-awaited FDA approval pathway.
Calvo B; Zuñiga L
BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
[TBL] [Abstract][Full Text] [Related]
14. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
15. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.
Grampp G; Ramanan S
BioDrugs; 2015 Dec; 29(6):365-72. PubMed ID: 26581551
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
17. Drug Development. Are trade secrets delaying biosimilars?
Price WN; Rai AK
Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
[No Abstract] [Full Text] [Related]
18. Biosimilars: how similar?
Strand V; Cronstein B
Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial development for biosimilars.
Alten R; Cronstein BN
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
[TBL] [Abstract][Full Text] [Related]
20. [Development and perspective for the Biosimilar medicines].
Takayasu Y; Tsukamoto T
Nihon Yakurigaku Zasshi; 2016 May; 147(5):303-9. PubMed ID: 27181727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
